For decades, respiratory syncytial virus was a wintertime nuisance for most families — a bad cold in kids, a cough in adults. But in older bodies, the same virus turns dangerous. It lands people in hospitals, fills intensive care beds, and kills. The numbers have always been stark: 64 million infections globally each year, 160,000 deaths. Yet for a long time, there was no vaccine.
That changed in 2023. GSK’s Arexvy became the first RSV shot approved anywhere in the world, cleared by the U.S. Food and Drug Administration for adults 60 and older. Pfizer’s Abrysvo followed weeks later. Then, in 2024, Moderna’s Mresvia joined them. Three vaccines, from three companies, aimed at the same vulnerable population. The science had finally caught up to the virus.
The U.S. Centers for Disease Control and Prevention took its time assessing the data. On June 15, 2024, it issued updated recommendations. The new guidance is not a blanket call for every older American to get the shot. It is targeted, layered, specific.
People aged 75 and older who have never received an RSV vaccine should get one. That is the clearest directive. For those aged 60 to 74, the CDC recommends vaccination only if they are at increased risk of severe RSV. That means people with chronic lung disease, heart disease, or other conditions that make a respiratory infection more dangerous. The CDC is not treating all older adults the same; it is drawing a line based on risk.
The logic is straightforward. Older bodies do not fight off respiratory viruses the way younger ones do. Immune systems weaken with age. Lungs lose elasticity. Chronic conditions compound the damage. RSV, which in a healthy adult causes a week of congestion and fatigue, can trigger pneumonia in an 80-year-old with heart failure. The vaccine is a tool to prevent that chain of events.
Arexvy has already received expanded approval in the United States for people aged 50 to 59 who are at increased risk. That is a younger group than the original target, but one that includes people with serious health problems. The same vaccine is approved in the European Union and Canada for adults 60 and older. The approvals are not identical across regions, but the pattern is the same: regulators see the vaccine as safe and effective, and they want it used where it matters most.
Clinical trials for all three vaccines showed strong protection against severe disease. The data convinced regulators. But real-world effectiveness will take time to measure. The CDC will watch hospitalizations this winter, track breakthrough infections, and adjust recommendations if needed. That is standard practice for any new vaccine.
The timing of the updated guidance matters. RSV season typically runs from fall through spring in the Northern Hemisphere. The CDC released its new recommendations in June, giving doctors and patients months to prepare before the virus starts circulating again. Pharmacies will stock the shots. Primary care offices will offer them. Public health campaigns will target the oldest and sickest Americans.
For people over 75 who skipped the vaccine last year, the message is now explicit: get it. For those between 60 and 74 with lung or heart disease, the same. For healthy 60-year-olds, the CDC is not pushing the shot. The recommendation draws a line, and that line is based on evidence, not caution.
RSV killed 160,000 people worldwide in a typical year before any vaccine existed. That number may now drop. But vaccines only work if people take them. The CDC has made its position clear. The next step belongs to patients and their doctors.
